Source: CureToday articles
The FDA has completed its 30-day review of an application for Hepzato in combination with standard of care in liver-dominant metastatic breast cancer.
Recent Content
- Results From ADVANCE-CIDP Trial Show IVIG 10% Effectively Treats CIDP Relapse
- First Patient Dosed With Azenosertib in Cyclin E1+ Ovarian Cancer
- Engineered Extracellular Vesicles May Be a New Approach to Treating MASH
- Blocking IL6 Pathway May Prevent Progression of Skin Ulcers in Calciphylaxis CKD-Related Disease
- Expert: Dual Interaction is Present Between Epilepsy and Menopause
- Pre-Treatment Baseline Screening for Breast Cancer–Related Lymphedema
- Dosing of PAS-004 Begins in Patients in MAPK-Driven Tumors
- Barriers to Bridging Clinical Trial Data to Routine Pharmacy Practice
- Enhancing Patient Care Through Multidisciplinary Team Collaboration in Management of NSCLC
- CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma